Ledenfrog

Excellent post. I really appreciate these frequent technical updates. I heartily agree with you. As word gets out and volume picks up I believe RVX is going to hit the street running. The Yale Club should be a catalyst as well as upcoming trial start and dosing announcements. Hopefully the Goldman Sachs crowd and other fund managers will pick up on this although that may not happen until RVX is Nasdaq listed. That and FDA approval may be what's keeping this off of their radar.

Looking forward to strong upward movement this week - as you pointed out - volume is the key.

Chicagoest